title: [Tissue plasminogen activator in treatment of fibrinous membranes after cataract surgery].
abstract: The aim of our study is estimation of the efficacy of recombinant tissue plasminogen activator for the treatment of fibrinous membranes following cataract extraction.
  
  
  METHODS
  The fibrinous membranes were formed, despite conventional antiinflammatory therapy, in 17 eyes after ECCE with IOL and in 3 eyes after ECCE without IOL. We injected the solution of recombinant tissue plasminogen activator-Actilyse (Boehringer Ingelheim) into the anterior chamber of 20 eyes after cataract surgery. Simultaneously, topical corticosteroid and cycloplegic therapy was continued. Routine follow-up included slit lamp examination, ophthalmoscopy and intraocular pressure measurement.
  
  
  RESULTS
  Injection of the solution of tissue plasminogen activator into anterior chamber of 20 eyes resulted in complete dissolution of the fibrinous membranes in 18 eyes within 1 day. In 7 eyes, within a few days after injection, fibrinous membrane recurred. In four of this cases durable effect of fibrin dissolution was obtained after multiple tPA injections. Finally, expectable stable result was obtained in 15 of 20 eyes.
  
  
  CONCLUSIONS
  Results of our study confirm high efficacy of recombinant tissue plasminogen activator in the treatment of fibrinous membranes after cataract surgery. Short term follow-up and small number of cases motivates further continuation of observation.
authors.affiliation: Katedry i Kliniki Okulistyki AM we Wrocławiu.
authors.forename: J
authors.initials: J
authors.lastname: Oficjalska-Młyńczak
authors.forename: J
authors.initials: J
authors.lastname: Marek
authors.forename: H
authors.initials: H
authors.lastname: Zajac-Pytrus
authors.forename: M H
authors.initials: MH
authors.lastname: Nizankowska
authors.forename: M
authors.initials: M
authors.lastname: Koziorowska
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000867:Anterior Chamber / Q000187:drug effects / Q000378:metabolism; D002387:Cataract Extraction / Q000009:adverse effects*; D005122:Exudates and Transudates; D005128:Eye Diseases / Q000209:etiology / Q000628:therapy; D005260:Female; D005337:Fibrin / Q000187:drug effects / Q000378:metabolism; D005342:Fibrinolysis; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D010960:Plasminogen Activators / Q000008:administration & dosage*; D011994:Recombinant Proteins; D012008:Recurrence; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*
chemical_list: D011994:Recombinant Proteins; D005337:Fibrin; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator